



Company Overview

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson and recently cleared by the FDA. The Company's first commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method cannot only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods. Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.

Soliton Announces First Follow-up Visit Conducted in the Pivotal Cellulite Clinical Trial

Nov 12 2019, 8:00 AM EST

Soliton Completes Treatment of All Patients in Pivotal Cellulite Trial

Nov 5 2019, 9:00 AM EST

Management Team

Walter V. Klemp

Co-Founder and Executive Chairman

Christopher Capelli, M.D.

Co-Founder, President and Chief Science Officer

Lori Bisson

Chief Financial Officer

Joe Tanner

Chief Operating Officer

Soliton, Inc.

5304 Ashbrook Dr.
Houston, TX 77081

Investor Relations

Lytham Partners, LLC
Joe Dorame
T: 602-889-9700

Stock Overview

Symbol	SOLY
Exchange	Nasdaq
Market Cap	182.87m
Last Price	\$10.80
52-Week	\$4.12 - \$29.00

11/19/2019 04:00 PM EST

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.